These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37835485)

  • 1. Holmium-166 Transarterial Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma: A Case Series.
    Vermeulen S; De Keukeleire K; Dorny N; Colle I; Van Den Bossche B; Nuttens V; Ooms D; De Bondt P; De Winter O
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer.
    Drescher R; Köhler A; Seifert P; Aschenbach R; Ernst T; Rauchfuß F; Freesmeyer M
    Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment delivery.
    Roosen J; Westlund Gotby LEL; Arntz MJ; Fütterer JJ; Janssen MJR; Konijnenberg MW; van Wijk MWM; Overduin CG; Nijsen JFW
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4705-4715. PubMed ID: 35829749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies.
    Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma.
    Sarwar A; Ali A; Ljuboja D; Weinstein JL; Shenoy-Bhangle AS; Nasser IA; Morrow MK; Faintuch S; Curry MP; Bullock AJ; Ahmed M
    J Vasc Interv Radiol; 2021 Nov; 32(11):1560-1568. PubMed ID: 34454031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated radioembolization in advanced liver cancer.
    Masthoff M; Schindler P; Harders F; Heindel W; Wilms C; Schmidt HH; Pascher A; Stegger L; Rahbar K; Wildgruber M; Köhler M
    Ann Transl Med; 2020 Sep; 8(17):1055. PubMed ID: 33145274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of the Bologna Experience in Radioembolization of Intrahepatic cholangiocarcinoma.
    Mosconi C; Cacioppa LM; Cappelli A; Gramenzi AG; Vara G; Modestino F; Renzulli M; Golfieri R
    Technol Cancer Res Treat; 2023; 22():15330338231155690. PubMed ID: 36927302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Results of Holmium-166 Radioembolization with Personalized Dosimetry for the Treatment of Hepatocellular Carcinoma.
    Kühnel C; Köhler A; Brachwitz T; Seifert P; Gühne F; Aschenbach R; Freudenberg R; Freesmeyer M; Drescher R
    J Pers Med; 2024 Jul; 14(7):. PubMed ID: 39064001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting outcomes of Yttrium-90 radioembolization in heavily pretreated patients with intrahepatic cholangiocarcinoma.
    Zhao K; Erinjeri JP; Sotirchos VS; Alexander ES; Moussa AM; Marinelli B; Ziv E; Sofocleous CT; Abou-Alfa GK; Jarnagin WR; Karimi A; Yarmohammadi H
    Abdom Radiol (NY); 2023 Jul; 48(7):2434-2442. PubMed ID: 37145313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving MRI-based dosimetry for holmium-166 transarterial radioembolization using a nonrigid image registration for voxelwise
    Roosen J; van Wijk MWM; Westlund Gotby LEL; Arntz MJ; Janssen MJR; Lobeek D; van de Maat GH; Overduin CG; Nijsen JFW
    Med Phys; 2023 Feb; 50(2):935-946. PubMed ID: 36202392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
    White J; Carolan-Rees G; Dale M; Patrick HE; See TC; Bell JK; Manas DM; Crellin A; Slevin NJ; Sharma RA
    J Vasc Interv Radiol; 2019 Aug; 30(8):1185-1192. PubMed ID: 31255499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.
    Taswell CS; Studenski M; Pennix T; Stover B; Georgiou M; Venkat S; Jones P; Zikria J; Thornton L; Yechieli R; Mohan P; Portelance L; Spieler B
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis.
    Mosconi C; Solaini L; Vara G; Brandi N; Cappelli A; Modestino F; Cucchetti A; Golfieri R
    Cardiovasc Intervent Radiol; 2021 May; 44(5):728-738. PubMed ID: 33709272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Radioembolization Planning and Treatment with Microspheres Containing Holmium-166: Determination of Renal and Intestinal Radionuclide Elimination, Effective Half-Life, and Regulatory Aspects.
    Kühnel C; Gühne F; Seifert P; Freudenberg R; Freesmeyer M; Drescher R
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France.
    Loffroy R; Ronot M; Greget M; Bouvier A; Mastier C; Sengel C; Tselikas L; Arnold D; Maleux G; Pelage JP; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; Urdániz M; Kaufmann N; Bilbao JI; Helmberger T; Vilgrain V;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):36-49. PubMed ID: 32975600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver.
    Orwat KP; Beckham TH; Cooper SL; Ashenafi MS; Anderson MB; Guimaraes M; Yamada R; Marshall DT
    J Gastrointest Oncol; 2017 Dec; 8(6):1072-1078. PubMed ID: 29299369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
    Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
    Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.